UK's Bingham expects Omicron vaccine impact to be known in a week
Reuters
Published Dec 01, 2021 15:03
Updated Dec 01, 2021 17:27
LONDON (Reuters) - Kate Bingham, the former head of the UK's COVID-19 Vaccine Taskforce who secured millions of doses for the country, said scientists should know within a week whether existing shots are effective against the Omicron variant of the coronavirus.
Bingham, a venture capitalist who backed multiple vaccines at the start of the pandemic to secure early access for Britain, said she currently expected that the leading shots would still show efficacy.
"The question is do they have the same level of efficacy?" she said in an interview at the Reuters Next conference on Wednesday.
Bingham, who has returned to her role as managing partner at SV Health Investors, said Britain had built up the capability to quickly test existing vaccines against new variants.
"It's not something you can do overnight, but we will get data, I would have thought within a week as to whether or not the vaccines work or don't," she said.
Under Bingham's leadership, the UK taskforce ordered vaccines as they were still being trialled, securing supplies from Pfizer (NYSE:PFE), AstraZeneca (NASDAQ:AZN), Moderna (NASDAQ:MRNA) and others to give Britain a head start in the rollout.
She said on Wednesday that she had backed the vaccine from French company Valneva, which differs from others by relying on an inactivated virus similar to flu vaccines, because having a varied portfolio would be useful when variants emerged.
Britain has since cancelled the order.
"The idea of having that as a potential vaccine in our portfolio, knowing it was going to come on stream later than the earlier ones, was precisely that you could deal with variants," she said.
She added that "unfortunately" the Valneva contract had been cancelled. "I wasn't part of the decision so I don't know the basis of it," she said. "But I would have thought that was a useful vaccine to have in our panoply of tools to actually address variants and future pandemic strains."
Get The App
To watch the Reuters Next conference please register here https://reutersevents.com/events/next/
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.